Syndax Pharmaceuticals has been granted a patent for a method to select cancer patients for treatment with a combination therapy of an HDAC inhibitor and a second therapeutic agent. The method involves examining specific cell types in peripheral blood samples to determine eligibility for treatment. GlobalData’s report on Syndax Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Syndax Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syndax Pharmaceuticals's grant share as of May 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Patient selection for combination therapy using hdac inhibitor and anti-pd-1 antibody
A recently granted patent (Publication Number: US12000829B2) discloses a method for selecting patients for combination therapy involving entinostat and an anti-PD-1 antibody. The method involves obtaining a peripheral blood sample from a cancer-diagnosed patient and measuring specific cell markers to determine eligibility for the therapy. If the percentage of certain cell types meets a predetermined threshold, the combination therapy can be administered. This method is particularly useful for patients who have not responded to prior therapies with anti-PD-1 antibodies, anti-PD-L1 antibodies, CTLA4-blocking antibodies, or combinations thereof.
Furthermore, the patent outlines specific details regarding the administration of entinostat and the anti-PD-1 antibody, pembrolizumab, in various cancer types such as lung cancer, melanoma, breast cancer, and ovarian cancer. The method allows for sequential or simultaneous administration of the drugs and provides flexibility in dosing regimens based on the patient's condition. By utilizing specific cell markers in the peripheral blood sample, healthcare providers can tailor the combination therapy to patients who are more likely to benefit from it, especially those who have shown resistance to previous treatments.
To know more about GlobalData’s detailed insights on Syndax Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
